

CLEO Files Patents for its Ovarian Cancer Screening Test

Highlights

- **CLEO has filed two new provisional patent applications to protect intellectual property arising from the development of its screening test**
- **Both filings relate to candidate biomarker combinations and their application to the early detection of ovarian cancer**
- **Intellectual property protection to be established ahead of initial proof-of-concept screening data, expected in early Q4 CY2026**

30th September 2026: Ovarian cancer diagnostics company, **Cleo Diagnostics Limited (ASX:COV)** (**CLEO** or **the Company**) is pleased announce that it has filed two new provisional patent applications to protect intellectual property (**IP**) arising from the development of its screening test.

Establishing CLEO's Screening IP Position

The filings follow CLEO's recent commencement of its screening development program (*refer to ASX Announcement dated 24th September 2026*) and establish an initial priority position around candidate biomarker combinations and their application to the early detection of ovarian cancer.

The Company also intends to file an international application under the Patent Cooperation Treaty (**PCT**) within the 12-month priority period as it seeks protection across key commercial markets. Importantly, the applications have been filed ahead of CLEO's initial proof-of-concept screening data, expected in Q4 CY2026. The Company continues to progress development while protecting IP generated through the program.

Development of the screening test builds on the biomarker platform and clinical expertise established through CLEO's more advanced Pre-Surgical Ovarian Cancer Test program, which is progressing towards FDA submission. The new filings further expand CLEO's existing IP portfolio and support the Company's broader strategy to apply its biomarker technology across multiple applications of the ovarian cancer detection pathway.

-ENDS-

This ASX announcement was authorised for release on behalf of the Cleo Diagnostics Ltd Board.

For more information, contact:

Richard Allman
Chief Executive Officer
+613 9614 0600
office@cleodx.com

Dayna Louca
Head of Corporate Development
+61 409 581 972
dayna.louca@cleodx.com

Cleo Diagnostics Ltd ASX:COV
Level 2, 480 Collins Street, Melbourne, VIC, 3000
ACN 655 717 169 **T** +61 3 9614 0600 **E** office@cleodx.com

Directors
Chair and Non-Executive Director **Adrien Wing**
Chief Executive Officer and Executive Director **Dr Richard Allman**
Chief Scientific Officer and Executive Director **Dr Andrew Stephens**
Non-Executive Director and Lead Medical Advisor **Professor Tom Jobling**
Non-Executive Director **Lucinda Nolan**

Forward Looking Statements: This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Cleo and certain of the plans and objectives of Cleo with respect to these items. These forward-looking statements are not historical facts but rather are based on Cleo's current expectations, estimates and projections about the industry in which Cleo operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Cleo, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Cleo cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Cleo only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Cleo will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

About Cleo Diagnostics Ltd ASX:COV

Cleo Diagnostics (ASX:COV) is an Australian medical technology company developing a simple blood test for the early and accurate detection of ovarian cancer – a disease with the highest five-year mortality rate of all cancers affecting women, with 51% of patients dying within five years, primarily due to late diagnosis and the lack of effective screening tools. Each year, hundreds of thousands of women are diagnosed only after the disease has advanced, highlighting a critical unmet need for earlier detection.

CLEO's patented technology is based on the CXCL10 biomarker, supported by over 15 years of scientific research and development. CXCL10 is produced early and at high levels in ovarian cancer but is largely absent in benign disease, making it a powerful discriminator between malignant and non-malignant growths.

The Company is executing a staged development strategy, starting with a pre-surgical triage test, then expanding into recurrence monitoring and ultimately global screening – creating clear value inflection points along the ovarian cancer detection pathway. CLEO is currently conducting its pivotal clinical trial, with FDA submission and commercial launch expected next year, reinforcing its goal to redefine the standard of care and enable earlier, smarter, life-changing diagnosis for women worldwide.

